zynex.com - רווח החברה לפני מסים, ריבית ופחת ZYXI

Zynex, Inc. (ZYXI) is valued by medical professionals for the effectiveness of NexWave systems, despite facing pricing pressure and staff turnover. The EBITDA_Co trend on this chart demonstrates the model's resilience to market shocks, with the 0.00 level serving as a critical mark. High profit predictability is driven by regular sales of therapy consumables, which guarantees a stable cash flow.

Steady growth in operating cash flow confirms the long-term reliability of Zynex, Inc. (ZYXI) for investor capital. Analyzing the trend in gross operating profit before depreciation and amortization allows for an assessment of the business's ability to offset cost inflation, which in this case is driven by software integration with insurance networks and an efficient sales force that protects margins from competitive pricing pressure.